275 related articles for article (PubMed ID: 17177205)
1. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.
Lin PP; Jaffe N; Herzog CE; Costelloe CM; Deavers MT; Kelly JS; Patel SR; Madewell JE; Lewis VO; Cannon CP; Benjamin RS; Yasko AW
Cancer; 2007 Feb; 109(3):603-11. PubMed ID: 17177205
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
3. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.
Wunder JS; Paulian G; Huvos AG; Heller G; Meyers PA; Healey JH
J Bone Joint Surg Am; 1998 Jul; 80(7):1020-33. PubMed ID: 9698007
[TBL] [Abstract][Full Text] [Related]
4. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases.
Hoffmann C; Ahrens S; Dunst J; Hillmann A; Winkelmann W; Craft A; Göbel U; Rübe C; Voute PA; Harms D; Jürgens H
Cancer; 1999 Feb; 85(4):869-77. PubMed ID: 10091764
[TBL] [Abstract][Full Text] [Related]
5. [Pediatric Ewing sarcoma of the rib: role of neoadjuvant chemotherapy in tumoral shrinking and sterilization. A case report].
Zidane A; Traibi A; Arsalane A; Atoini F; Ouriachi F; Hammoumi M; Kabiri EH
Rev Pneumol Clin; 2011 Dec; 67(6):371-4. PubMed ID: 22137283
[TBL] [Abstract][Full Text] [Related]
6. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.
Bosma SE; Rueten-Budde AJ; Lancia C; Ranft A; Dirksen U; Krol AD; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Fiocco M
Pediatr Blood Cancer; 2019 Nov; 66(11):e27943. PubMed ID: 31389188
[TBL] [Abstract][Full Text] [Related]
7. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
[TBL] [Abstract][Full Text] [Related]
8. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol.
Biswas B; Rastogi S; Khan SA; Shukla NK; Deo SV; Agarwala S; Sharma DN; Thulkar S; Vishnubhatla S; Pathania S; Bakhshi S
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):722-9. PubMed ID: 24919857
[TBL] [Abstract][Full Text] [Related]
9. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.
Shamberger RC; Laquaglia MP; Krailo MD; Miser JS; Pritchard DJ; Gebhardt MC; Healey JH; Tarbell NJ; Fryer CJ; Meyers PA; Grier HE
J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1154-61. PubMed ID: 10838532
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy.
Delepine N; Delepine G; Cornille H; Voisin MC; Brun B; Desbois JC
J Chemother; 1997 Oct; 9(5):352-63. PubMed ID: 9373791
[TBL] [Abstract][Full Text] [Related]
11. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
12. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.
Foulon S; Brennan B; Gaspar N; Dirksen U; Jeys L; Cassoni A; Claude L; Seddon B; Marec-Berard P; Whelan J; Paulussen M; Streitbuerger A; Oberlin O; Juergens H; Grimer R; Le Deley MC
Eur J Cancer; 2016 Jul; 61():128-36. PubMed ID: 27176931
[TBL] [Abstract][Full Text] [Related]
13. Risk analysis factors for local recurrence in Ewing's sarcoma: when should adjuvant radiotherapy be administered?
Albergo JI; Gaston CLL; Parry MC; Laitinen MK; Jeys LM; Tillman RM; Abudu AT; Grimer RJ
Bone Joint J; 2018 Feb; 100-B(2):247-255. PubMed ID: 29437069
[TBL] [Abstract][Full Text] [Related]
14. An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma.
Paulino AC; Nguyen TX; Mai WY
Pediatr Blood Cancer; 2007 Apr; 48(4):423-9. PubMed ID: 16421909
[TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.
Albergo JI; Gaston CL; Laitinen M; Darbyshire A; Jeys LM; Sumathi V; Parry M; Peake D; Carter SR; Tillman R; Abudu AT; Grimer RJ
Bone Joint J; 2016 Aug; 98-B(8):1138-44. PubMed ID: 27482030
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative Electron-Beam Radiation Therapy for Pediatric Ewing Sarcomas and Rhabdomyosarcomas: Long-Term Outcomes.
Sole CV; Calvo FA; Polo A; Cambeiro M; Gonzalez C; Desco M; Martinez-Monge R
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1069-1076. PubMed ID: 26194682
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in primary nonmetastatic Ewing sarcoma of the rib in children and young adults.
Qureshi SS; Kembhavi S; Vora T; Ramadwar M; Laskar S; Talole S; Kurkure P
J Pediatr Surg; 2013 Apr; 48(4):764-70. PubMed ID: 23583131
[TBL] [Abstract][Full Text] [Related]
18. Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
Raciborska A; Bilska K; Drabko K; Chaber R; Sobol G; Pogorzała M; Wyrobek E; Połczyńska K; Rogowska E; Rodriguez-Galindo C; Wożniak W
Pediatr Blood Cancer; 2014 Dec; 61(12):2170-4. PubMed ID: 25163763
[TBL] [Abstract][Full Text] [Related]
19. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy.
Bacci G; Ferrari S; Mercuri M; Bertoni F; Picci P; Manfrini M; Gasbarrini A; Forni C; Cesari M; Campanacci M
Acta Orthop Scand; 1998 Jun; 69(3):230-6. PubMed ID: 9703394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
